Eledon Pharmaceuticals - ELDN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.67
  • Forecasted Upside: 359.32%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.54
▲ +0.07 (2.83%)

This chart shows the closing price for ELDN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eledon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELDN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELDN

Analyst Price Target is $11.67
▲ +359.32% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Eledon Pharmaceuticals in the last 3 months. The average price target is $11.67, with a high forecast of $16.00 and a low forecast of $9.00. The average price target represents a 359.32% upside from the last price of $2.54.

This chart shows the closing price for ELDN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Eledon Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00Low
5/7/2024HC WainwrightBoost TargetBuy ➝ Buy$13.00 ➝ $16.00Low
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00Low
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$13.00Low
10/24/2023HC WainwrightLower TargetBuy ➝ Buy$25.00 ➝ $13.00Low
9/27/2023Noble FinancialInitiated CoverageOutperform$10.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$9.00Low
5/15/2023Cantor FitzgeraldReiterated RatingOverweightLow
12/15/2022HC WainwrightReiterated RatingBuyLow
8/2/2022HC WainwrightReiterated RatingBuy$25.00Low
6/1/2022SVB LeerinkLower TargetOutperform$33.00 ➝ $26.00High
5/13/2022Cantor FitzgeraldInitiated CoverageOverweight$25.00 ➝ $15.00Low
3/29/2022Cantor FitzgeraldReiterated RatingOverweightLow
3/25/2022Lifesci CapitalReiterated RatingOutperformMedium
1/14/2022HC WainwrightReiterated RatingBuy$25.00Low
11/24/2021HC WainwrightLower TargetBuy$35.00 ➝ $25.00Low
11/14/2021SVB LeerinkReiterated RatingBuy$33.00Medium
4/27/2021SVB LeerinkLower TargetOutperform$34.00 ➝ $33.00High
3/29/2021SVB LeerinkReiterated RatingBuy$34.00Low
3/22/2021Cantor FitzgeraldInitiated CoverageOverweight$25.00Medium
3/18/2021Lifesci CapitalReiterated RatingOutperformHigh
2/8/2021SVB LeerinkInitiated CoverageOutperform$34.00Low
(Data available from 7/14/2019 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/16/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/15/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/14/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Eledon Pharmaceuticals logo
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Read More

Today's Range

Now: $2.54
Low: $2.43
High: $2.57

50 Day Range

MA: $2.65
Low: $2.19
High: $3.12

52 Week Range

Now: $2.54
Low: $1.07
High: $3.35

Volume

63,679 shs

Average Volume

121,442 shs

Market Capitalization

$63.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Eledon Pharmaceuticals?

The following Wall Street analysts have issued reports on Eledon Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, and Noble Financial.
View the latest analyst ratings for ELDN.

What is the current price target for Eledon Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Eledon Pharmaceuticals in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 359.3%. HC Wainwright has the highest price target set, predicting ELDN will reach $16.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $9.00 for Eledon Pharmaceuticals in the next year.
View the latest price targets for ELDN.

What is the current consensus analyst rating for Eledon Pharmaceuticals?

Eledon Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ELDN will outperform the market and that investors should add to their positions of Eledon Pharmaceuticals.
View the latest ratings for ELDN.

What other companies compete with Eledon Pharmaceuticals?

How do I contact Eledon Pharmaceuticals' investor relations team?

Eledon Pharmaceuticals' physical mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The company's listed phone number is (949) 238-8090 and its investor relations email address is [email protected]. The official website for Eledon Pharmaceuticals is novustherapeutics.com. Learn More about contacing Eledon Pharmaceuticals investor relations.